Reagent to confirm Lupus anticoagulant
Lupus anticoagulant is the most common cause of acquired thrombophilia. The incidence of lupus anticoagulant in the general population is 1% to 2%. Chronic lupus anticoagulant is associated with a 30% risk of venous thromboembolic disease or arterial thrombosis, including stroke and myocardial infarction, as well as with chronic spontaneous abortion. For use in the platelet neutralisation procedure (PNP), Lupus Anticoagulant Confirmation Reagent (LA-CR) is used to determine if the prolongation of an activated partial thromboplastin time (APTT) is due to the presence of lupus anticoagulant. The reagent is a lyophilised preparation of phosphatidyl enhanced platelet phospholipid, the addition of which will shorten the APTT time in the presence of the lupus anticoagulant. Thus, the platelet neutralisation procedure is a valuable diagnostic test to confirm lupus anticoagulant.